Goldfinch Bio Announces Upcoming Presentations at the 13th International Podocyte Conference
The oral presentation will detail how Goldfinch Bios novel transplanted human organoid approach for preclinical pharmacokinetic (PK) and PD studies improves upon the limited predictive power and translatability of standard animal model studies to the human condition.
Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present new data establishing the feasibility of using transplanted human organoids to assess the pharmacodynamic (PD) efficacy of novel therapeutic candidates, including GFB-887, at the 13th International Podocyte Conference, taking place July 27-31, 2021, online and at the University of Manchester, UK. GFB-887 is Goldfinch Bio’s highly potent and selective inhibitor of Transient Receptor Potential Canonical Channel 5 (TRPC5), currently in Phase 2 clinical development for the treatment of focal segmental glomerular disease (FSGS) and diabetic nephropathy (DN)1.
The oral presentation will detail how Goldfinch Bio’s novel transplanted human organoid approach for preclinical pharmacokinetic (PK) and PD studies improves upon the limited predictive power and translatability of standard animal model studies to the human condition. Data from the Company’s in vivo evaluation of GFB-887 demonstrate how this widely applicable transplanted human organoid approach can be used to establish the human relevance of an investigational new drug before its advancement into clinical trials.
“We are proud to take the first step toward a future where confidence in bringing novel drugs in kidney diseases to the clinic may be derived, at least in part, from establishing preclinical efficacy in transplanted human organoids,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio. “Having proven the feasibility and value of transplanted human organoids in the assessment of preclinical PD efficacy with GFB-887, we believe our innovative approach has the potential to become an integral component of a broad range of drug discovery programs, translating to more efficient, cost-effective development of new potential medicines for the treatment of kidney diseases.”
Also at the conference, Goldfinch Bio will present an e-poster presentation detailing its approach to developing novel medicines for podocytopathies, including GFB-887. This presentation will review previously reported data from Goldfinch Bio’s first-in-human, randomized, double-blind, placebo-controlled, single-ascending dose trial Phase 1 trial of GFB-887 and will detail the study design of TRACTION-2, the ongoing Phase 2 trial evaluating GFB-887 in adult patients with FSGS and DN.
Details of the presentations are as follows:
Abstract Title: Transplanted human organoids empower PK/PD assessment of drug candidate for the clinic
Session Title: Session 4.2 Drug Development
Date and Time: Thursday, July 29th at 4:45 PM BST (11:45 AM EDT)
Location: Online
Abstract Title: A Precision Medicine Approach to Developing Novel Medicines for Podocytopathies: The GFB887 Clinical Development Program
Location: Online
Poster Number: P18
About Goldfinch Bio
Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse kidney disease patient populations to identify subsets most likely to respond to our treatments. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies. Visit us at www.goldfinchbio.com to learn more.
1 Patients diagnosed with treatment resistant minimal change disease, which is considered a subset of FSGS, are also being enrolled in the Phase 2 clinical trial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005332/en/